MONDAY, Nov. 25, 2013 (HealthDay News) -- A procedure used to
treat bleeding stomach ulcers could stand as a potential weapon in
the battle of the bulge, a small preliminary study suggests.
The procedure is called gastric artery embolization. It involves
using a catheter to introduce some "obstructive agent" -- like tiny
beads or gel foam -- into an artery supplying the stomach.
In the new study, researchers reviewed the records of 14
patients who underwent embolization of the left gastric artery to
treat stomach bleeding. Over the next three months, those patients
lost 8 percent of their body weight, on average.
That compared with a 1 percent weight loss among 18 patients who
were treated for the same problem, but had a different artery
That difference is "intriguing," the researchers said, because
the left gastric artery supplies the area of the stomach that
churns out the appetite-boosting hormone ghrelin.
It's possible that the reduced blood flow to that stomach region
curbed patients' ghrelin production, according to lead researcher
Dr. Rahmi Oklu, an assistant professor of radiology at Harvard
Medical School, in Boston.
However, no one is saying embolization is the new route to a
"This is just an observation that deserves more study," Oklu said. "Our point is just to say, let's look at this. It still needs to be rigorously investigated."
The findings will be presented at the annual meeting of the
Radiological Society of North America, being held next week in
Chicago. In general, studies presented at meetings are considered
preliminary until they are published in a peer-reviewed
Since the results were based on patient records, Oklu's team
does not actually know if embolization lowered people's ghrelin
But animal studies suggest that could be the case, according to
Dr. Mitchell Roslin, chief of bariatric (weight-loss) and metabolic
surgery at Lenox Hill Hospital, in New York City.
"There is some science behind this," said Roslin, who was not involved in the study.
Still, he doubted that embolization will help obese people see
lasting weight loss. Ghrelin is only one of the hormones involved
in appetite and metabolism. When one hormone's activity is altered,
the body generally finds a way to compensate.
"With weight loss, you have to look at the long term," Roslin said. "My guess is, the response with [embolization] will be fleeting."
Gastric embolization is a minimally invasive procedure, and Oklu
said it's a generally safe, same-day procedure. But it is normally
used to treat bleeding -- no one knows how it would work out as an
Researchers have, however, already taken a first, small step.
Earlier this year, investigators reported on the first five
patients to have gastric artery embolization specifically to manage
In that study, reported at an American College of Cardiology
meeting, patients lost an average of 45 pounds in six months, and
there were no complications. However, patients' ghrelin levels,
which had dropped in the first few months after the procedure, were
on the rise again by the sixth month.
And that is what you'd expect when tinkering with the hormone,
according to Lenox Hill's Roslin. "I really can't imagine this will
hold up in the long term," he said.
But study author Oklu said that even if ghrelin levels don't
stay down, the procedure might give some people the weight loss
jump-start they need.
And, he said, it might be appealing to patients who want an
alternative to the extensive surgeries that, right now, stand as
the only option for substantial, long-term weight loss.
The U.S. National Heart, Lung, and Blood Institute has more on
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Publishing. All rights reserved.